Research programme: PPAR delta agonists - sanofi-aventis
Latest Information Update: 04 Nov 2017
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in France
- 13 Mar 2009 Preclinical development ongoing